BioSpace News Archive

Bristol Myers Squibb (NYSE: BMY) today announced an update on CheckMate -548, a Phase 3 trial evaluating the addition of Opdivo (nivolumab) to the current standard of care (temozolomide and radiation therapy) versus placebo plus the standard of care in patients with newly diagnosed glioblastoma multiforme (GBM) with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation following surgical resection of the tumor

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today progress from its ongoing license agreement with AstraZeneca (LSE: AZN) (STO: AZN) (NASDAQ: AZN) under which the program has achieved a preclinical milestone.

DermOQ Inc., the oxygen skin care provider of Oxygen Lab™ topical skin care products to physician’s offices, spas, and aestheticians and Element Eight® prestige skin care announced today that it had closed the acquisition of ECHO2 Plus® and Oxyceuticals™ oxygen facial treatment product lines from Skin Products, Inc. for an undisclosed amount.

Study will evaluate the efficacy and safety of NERLYNX® and FASLODEX® in metastatic HR-positive, HER2-negative breast cancer patients selected by the CELsignia® Test

Progressive Care Inc., a personalized healthcare services and technology company, is pleased to announce that the Company has completed its move into its new 11,000 sq ft pharmacy space in Hallandale Beach, FL.

Glaukos Corporation announced that its management is scheduled to virtually participate in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 11:00 a.m. PST.

Adastra Labs Holdings Ltd. (CSE:XTRX)(FRANKFURT:D2EP) (“Adastra”) a Health Canada Licensed cannabis processing and analytical testing services Company, is pleased to announce the signing of a term sheet for the acquisition of Phyto Extractions Brands (“Phyto Extractions”) and permitting of its hydrocarbon extraction expansion.

Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Dr. Michael Dunne has resigned from his role as Chief Scientific Officer of the Company, effective December 21, 2020.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the companies’ COVID-19 Vaccine from production facilities in the U.S. This agreement brings the total number of doses to be delivered to the U.S. to 200 million

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today res